Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 38,172 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 38,172 shares of the business’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $33.75, for a total value of $1,288,305.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $821,913.75. This represents a 61.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total transaction of $1,127,632.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Up 0.8%

NewAmsterdam Pharma stock traded up $0.26 during mid-day trading on Tuesday, reaching $32.63. 421,344 shares of the company’s stock traded hands, compared to its average volume of 750,314. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00. The stock has a 50 day moving average of $35.58 and a two-hundred day moving average of $31.17. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -15.92 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. As a group, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. raised its holdings in shares of NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares in the last quarter. Capital World Investors boosted its position in shares of NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares during the period. Jennison Associates LLC grew its stake in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Wellington Management Group LLP grew its position in shares of NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NAMS shares. Citigroup lifted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Needham & Company LLC boosted their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. The Goldman Sachs Group increased their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Stifel Nicolaus increased their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and a consensus price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.